Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients - Summary - MDSpire

Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients

  • By

  • Sarah E. Glynn

  • Ralph D’Agostino Jr

  • Claire M. Lanier

  • Ariel R. Choi

  • Michael Farris

  • Mohammed Abdulhaleem

  • Patrick Young

  • Yuezhu Wang

  • Margaret Smith

  • Jimmy Ruiz

  • Thomas Lycan

  • William Jeffrey Petty

  • Christina K. Cramer

  • Stephen B. Tatter

  • Adrian W. Laxton

  • Jaclyn J. White

  • Jing Su

  • Christopher T. Whitlow

  • Fei Xing

  • Michael D. Chan

  • Corbin A. Helis

  • May 25, 2026

  • 0 min

Share

Objective:

To evaluate whether genomic profiling can predict the risk of neurologic death in patients with metastatic non-small cell lung cancer (NSCLC) who develop brain metastases, thereby informing treatment strategies.

Approach:
    Key Findings:
    • Approximately 20% of patients with brain metastases from NSCLC experience neurologic death, highlighting the need for effective risk stratification.
    • Genomic profiling can differentiate patients based on risk for neurologic death, potentially guiding clinical decisions.
    • A genetic risk score was developed to stratify patients into high, moderate, and low risk for neurologic death, which may inform treatment approaches.
    Interpretation:

    The study suggests that genomic profiling may be a useful tool in predicting neurologic mortality in NSCLC patients with brain metastases, potentially leading to tailored treatment strategies.

    Limitations:
    • Retrospective design may introduce bias, affecting the generalizability of the findings.
    • Findings need validation in larger, prospective studies to confirm the utility of the genetic risk score.
    Conclusion:

    Genomic risk assessment via liquid biopsy could aid in identifying NSCLC patients at higher risk for neurologic death, potentially guiding treatment decisions.

Original Source(s)

Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients

  • by Sarah E. Glynn, Ralph D’Agostino Jr, Claire M. Lanier, Ariel R. Choi, Michael Farris, Mohammed Abdulhaleem, Patrick Young, Yuezhu Wang, Margaret Smith, Jimmy Ruiz, Thomas Lycan, William Jeffrey Petty, Christina K. Cramer, Stephen B. Tatter, Adrian W. Laxton, Jaclyn J. White, Jing Su, Christopher T. Whitlow, Fei Xing, Michael D. Chan, Corbin A. Helis

  • May 25, 2026

Related Content

Preliminary evaluation of DeepSeek-R1 and GPT-5.3 in selected PET/CT clinical scenarios: patient preparation, report interpretation, and diagnostic reasoning

Gilead and Merck’s latest trial success and flop

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study